DSIP (Delta sleep-inducing peptide) is a well-known neuromodulator and natural sleep-promoting nonapeptide with many other physiologic functions. It is typically found in the brain and easily passes the blood-brain barrier. It has been discovered and heavily studied for over 40 years.
It has been used for the treatment of poor sleep, pain conditions, stress-related symptoms, low testosterone (via stimulation of LH), and even sometimes as an antioxidant and anti-cancer protein. It exhibits a pronounced stress protective action and decreases stress-induced metabolic and functional disorders in human and animal organisms exposed to a variety of stresses. It has also been shown in research to improve hormone levels and physical performance.
Benefits of DSIP:
- Can restore disturbed sleep patterns
- Can promote LH and GH release
- Can reduce persistent/chronic pain
- Can modulate cortisol production
DSIP has been described as a sleep-promoting substance rather than a sedative. There is a modulating effect on sleep and wake functions with greater activity in circumstances where sleep is disturbed. There are essentially 5 stages of sleep, these can be broken down into 2 categories REM and NREM sleep. These translate to Random Eye Movement and Non-Random Eye movement sleep. The problem with many sleep aids is that they change the time or duration of these sleep cycles. The problem with this is these cycles are ALL associated with important physiological processes and anabolic hormone production. DSIP does not change these sleep stages. It increases the ability to go to sleep and offers a more restful sleep.
It is involved in neuroendocrine regulation and release of anterior pituitary hormones. In humans, DSIP influences the secretion of adrenocorticotropic hormone (ACTH), luteinizing hormone (LH) and growth hormone (GH). It also plays a role in the regulation of circadian rhythms. Administration of DSIP seems to improve the hormone production/regulation in these glands. For example, it increases LH and growth hormone production while decreasing somatostatin. This results in increased production of desirable hormones (LH, GH), and decreased the production of undesirable ones (cortisol and somatostatin).
Gimble JM, Ptitsyn AA, Goh BC, Hebert T, Yu G, Wu X, Zvonic S, Shi X-M and Floyd ZE (2009). “Delta sleep-inducing peptide and glucocorticoid-induced leucine zipper: potential links between circadian mechanisms and obesity?”. Obesity reviews 10: 46–51
Kovalzon VM (1994). “DSIP: a sleep peptide or unknown hypothalamic hormone?”. J. Evol. Biochem. Physiol. 30: 195–199.
Pollard BJ and Pomfrett CJD (2001). “Delta sleep-inducing peptide”. Eur. J. Anaesthesiol. 18: 419–422.
Steiger A and Holsboer F (1997). “Neuropeptides and human sleep”. Sleep 20: 1038–1052.
Courtesy of: https://www.transformyouaz.com